Clinical and histologic evaluation of an enamel matrix derivative combined with a biphasic calcium phosphate for the treatment of human intrabony periodontal defects.

BACKGROUND The goal of this study was to evaluate clinically and histologically the healing of advanced intrabony defects following regenerative periodontal surgery with an enamel matrix derivative (EMD) combined with a new biphasic calcium phosphate (BCP). METHODS Ten subjects, each of them displaying advanced combined 1- and 2-wall intrabony defects around teeth scheduled for extraction because of advanced chronic periodontitis and further prosthodontic considerations, were included in the study. The defects were consecutively treated with a combination of EMD + BCP. A notch was placed at the most apical extent of the calculus present on the root surface or at the most apical part of the defect (if no calculus was present) to serve as a reference for the histologic evaluation. At 9 months after regenerative surgery, nine of 10 teeth were extracted with some of their surrounding soft and hard tissues and processed for histologic evaluation. RESULTS There were no adverse effects related to EMD or the graft material used in any of the treated subjects. One tooth was not extracted because of the excellent clinical outcome. The clinical measurements at the nine biopsied teeth demonstrated a mean probing depth reduction of 3.3 +/- 1.4 mm and a mean clinical attachment level gain of 3.0 +/- 1.6 mm. The histologic findings indicated formation of cementum with inserting collagen fibers to a varying extent. A long junctional epithelium was observed in three of the nine biopsies. Mean new connective tissue attachment (i.e., new cementum with inserting collagen fibers) varied from 0.0 to 2.1 mm. The amount of newly formed bone was limited and varied from 0.0 to 0.7 mm. At 9 months, graft particles were still present and were mostly encapsulated in connective tissue, whereas formation of bone around the graft particles was observed only occasionally. Direct contact between the graft particles and the root surface (cementum or dentin) was not observed in any of the analyzed specimens. CONCLUSIONS The combination of EMD with a BCP bone substitute did not interfere with the regenerative potential reported for EMD and may result in formation of new cementum with an associated periodontal ligament. However, the combination of EMD + BCP resulted in no to minimal new bone formation.

[1]  A. Sculean,et al.  Effect of an enamel matrix protein derivative (Emdogain) on ex vivo dental plaque vitality. , 2008, Journal of clinical periodontology.

[2]  F. Schwarz,et al.  Guided bone regeneration at dehiscence-type defects using biphasic hydroxyapatite + beta tricalcium phosphate (Bone Ceramic) or a collagen-coated natural bone mineral (BioOss Collagen): an immunohistochemical study in dogs. , 2007, International journal of oral and maxillofacial surgery.

[3]  M. Dard,et al.  Evaluation of a novel biphasic calcium phosphate in standardized bone defects: a histologic and histomorphometric study in the mandibles of minipigs. , 2007, Clinical oral implants research.

[4]  B. Willershausen,et al.  Treatment of Intrabony Defects Using Guided Tissue Regeneration and Autogenous Spongiosa Alone or Combined With Hydroxyapatite/β-Tricalcium Phosphate Bone Substitute or Bovine-Derived Xenograft. , 2007, Journal of periodontology.

[5]  L. Trombelli,et al.  Effect of autogenous cortical bone particulate in conjunction with enamel matrix derivative in the treatment of periodontal intraosseous defects. , 2007, Journal of periodontology.

[6]  U. Schlagenhauf,et al.  Primary flap closure combined with Emdogain alone or Emdogain and Cerasorb in the treatment of intra-bony defects. , 2006, Journal of clinical periodontology.

[7]  N. Lang,et al.  Pattern of mineralization after regenerative periodontal therapy with enamel matrix proteins. , 2006, European journal of oral sciences.

[8]  A. Sculean,et al.  Clinical evaluation of an enamel matrix protein derivative combined with either a natural bone mineral or beta-tricalcium phosphate. , 2005, Journal of periodontology.

[9]  Z. Majzoub,et al.  Two patterns of histologic healing in an intrabony defect following treatment with enamel matrix derivative: a human case report. , 2005, The International journal of periodontics & restorative dentistry.

[10]  B. Pjetursson,et al.  Effects of enamel matrix proteins on tissue formation along the roots of human teeth. , 2005, Journal of periodontal research.

[11]  A. Sculean,et al.  Clinical and histologic evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. , 2005, The International journal of periodontics & restorative dentistry.

[12]  T. Karring,et al.  Formation of human cementum following different modalities of regenerative therapy , 2005, Clinical Oral Investigations.

[13]  M. Mills,et al.  Clinical evaluation of demineralized freeze-dried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans. , 2004, Journal of periodontology.

[14]  J. C. Joly,et al.  The influence of enamel matrix derivative associated with insulin-like growth factor-I on periodontal ligament fibroblasts. , 2004, Journal of periodontology.

[15]  A. Forlino,et al.  Effect of enamel matrix derivative on human periodontal fibroblasts: proliferation, morphology and root surface colonization. An in vitro study. , 2003, Journal of periodontal research.

[16]  G. Zucchelli,et al.  Enamel matrix proteins and bovine porous bone mineral in the treatment of intrabony defects: a comparative controlled clinical trial. , 2003, Journal of periodontology.

[17]  Markus B Hürzeler,et al.  Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study. , 2003, Journal of clinical periodontology.

[18]  A. Sculean,et al.  Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative combined with a bovine-derived xenograft. , 2003, The International journal of periodontics & restorative dentistry.

[19]  A. Ohazama,et al.  Participation of endogenous IGF-I and TGF-beta 1 with enamel matrix derivative-stimulated cell growth in human periodontal ligament cells. , 2003, Journal of periodontal research.

[20]  A. Sculean,et al.  Antibacterial effect of an enamel matrix protein derivative on in vivo dental biofilm vitality , 2002, Clinical Oral Investigations.

[21]  J. Mellonig,et al.  Clinical comparison of an enamel matrix derivative used alone or in combination with a bovine-derived xenograft for the treatment of periodontal osseous defects in humans. , 2002, Journal of periodontology.

[22]  N. Lang,et al.  Enamel matrix proteins in the regenerative therapy of deep intrabony defects. , 2002, Journal of clinical periodontology.

[23]  E. Reich,et al.  Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. A prospective controlled clinical study. , 2001, Journal of clinical periodontology.

[24]  P. Bartold,et al.  Enamel matrix derivative induces matrix synthesis by cultured human periodontal fibroblast cells. , 2001, Journal of periodontology.

[25]  S. Lyngstadaas,et al.  Autocrine growth factors in human periodontal ligament cells cultured on enamel matrix derivative. , 2001, Journal of clinical periodontology.

[26]  L. Wolff,et al.  Enamel matrix derivative in the treatment of human intrabony osseous defects. , 2000, Journal of periodontology.

[27]  T. Karring Regenerative periodontal therapy. , 2000, Journal of the International Academy of Periodontology.

[28]  D. Carnes,et al.  Porcine fetal enamel matrix derivative stimulates proliferation but not differentiation of pre-osteoblastic 2T9 cells, inhibits proliferation and stimulates differentiation of osteoblast-like MG63 cells, and increases proliferation and differentiation of normal human osteoblast NHOst cells. , 2000, Journal of periodontology.

[29]  G. Rasperini,et al.  Comparison of treatments of infrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap. A pilot study. , 2000, Journal of clinical periodontology.

[30]  A. Sculean,et al.  Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative (Emdogain). , 2000, The International journal of periodontics & restorative dentistry.

[31]  D. M. Burns,et al.  Cytostatic action of enamel matrix derivative (EMDOGAIN) on human oral squamous cell carcinoma-derived SCC25 epithelial cells. , 2000, Journal of periodontal research.

[32]  Z. Aleksic,et al.  A comparison between enamel matrix proteins used alone or in combination with bovine porous bone mineral in the treatment of intrabony periodontal defects in humans. , 2000, Journal of periodontology.

[33]  J. Mellonig,et al.  Histologic evaluation of periodontal healing in humans following regenerative therapy with enamel matrix derivative. A 10-case series. , 2000, Journal of periodontology.

[34]  J. Wennström,et al.  The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study. , 1999, Journal of clinical periodontology.

[35]  G. Armitage,et al.  Development of a classification system for periodontal diseases and conditions. , 1999, Annals of periodontology.

[36]  T. Karring,et al.  Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration. , 1999, Journal of periodontal research.

[37]  K. Selvig,et al.  Periodontal wound healing and regeneration. , 1999, Periodontology 2000.

[38]  J. Mellonig Enamel matrix derivative for periodontal reconstructive surgery: technique and clinical and histologic case report. , 1999, The International journal of periodontics & restorative dentistry.

[39]  L. Heijl Periodontal regeneration with enamel matrix derivative in one human experimental defect. A case report. , 1997, Journal of clinical periodontology.

[40]  G. Heden,et al.  Enamel matrix derivative (EMDOGAIN) in the treatment of intrabony periodontal defects. , 1997, Journal of clinical periodontology.

[41]  C. Mangano,et al.  Clinical and histologic aspects of biphasic calcium phosphate ceramic (BCP) used in connection with implant placement. , 1996, Biomaterials.

[42]  S. Lindskog,et al.  Smear removal and collagen exposure after non-surgical root planing followed by etching with an EDTA gel preparation. , 1996, Journal of periodontology.

[43]  K. Lynch,et al.  Tissue response to biphasic calcium phosphate ceramic with different ratios of HA/beta TCP in periodontal osseous defects. , 1992, Journal of periodontology.

[44]  H Löe,et al.  The Gingival Index, the Plaque Index and the Retention Index Systems. , 1967, Journal of periodontology.

[45]  S. Froum,et al.  A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: a 12-month re-entry study. , 2001, Journal of periodontology.

[46]  V. Everts,et al.  Enamel matrix-derived protein stimulates attachment of periodontal ligament fibroblasts and enhances alkaline phosphatase activity and transforming growth factor beta1 release of periodontal ligament and gingival fibroblasts. , 2000, Journal of periodontology.